Toleranzia AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TOL.ST research report →
Companywww.toleranzia.com
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease.
- CEO
- Charlotte Fribert
- IPO
- 2015
- Employees
- 10
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $129.25M
- P/E
- -12.39
- P/S
- 10.47
- P/B
- 0.74
- EV/EBITDA
- -12.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 11.17%
- Op Margin
- -83.67%
- Net Margin
- -84.45%
- ROE
- -5.90%
- ROIC
- -5.78%
Growth & Income
- Revenue
- $30.03M · -41.03%
- Net Income
- $-9,436,000 · -26.50%
- EPS
- $-0.04 · 20.36%
- Op Income
- $-10,248,000
- FCF YoY
- 29.04%
Performance & Tape
- 52W High
- $0.72
- 52W Low
- $0.27
- 50D MA
- $0.47
- 200D MA
- $0.50
- Beta
- 0.98
- Avg Volume
- 2.96M
Get TickerSpark's AI analysis on TOL.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TOL.ST Coverage
We haven't published any research on TOL.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TOL.ST Report →